Get the Stockscreener App
27.20
2.95%
0.78
Immunome Inc stock is traded at $27.20, with a volume of 759.56K.
It is up +2.95% in the last 24 hours and up +20.41% over the past month.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
See More
Previous Close:
$26.42
Open:
$26.38
24h Volume:
759.56K
Relative Volume:
0.56
Market Cap:
$3.09B
Revenue:
$4.02M
Net Income/Loss:
$-224.59M
P/E Ratio:
-11.43
EPS:
-2.3795
Net Cash Flow:
$-205.52M
1W Performance:
+8.67%
1M Performance:
+20.41%
6M Performance:
+22.74%
1Y Performance:
+173.64%
1-Day Range:
$25.59
$27.30
1-Week Range:
$24.49
$28.62
52-Week Range:
$8.665
$28.62
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
27.20 | 3.18B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-26 | Initiated | Barclays | Overweight |
| Feb-12-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5% - Stock Titan
Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A - Stock Titan
HC Wainwright Issues Negative Forecast for Immunome Earnings - MarketBeat
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon (IMNM) - Seeking Alpha
Renaissance Technologies LLC Makes New Investment in Immunome, Inc. $IMNM - MarketBeat
Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 Shares - MarketBeat
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 11,048 Shares - MarketBeat
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells $1,633,892.93 in Stock - MarketBeat
Immunome director Isaac Barchas sells over $2.1m in shares By Investing.com - Investing.com South Africa
Immunome director Isaac Barchas sells over $2.1m in shares - Investing.com
Immunome, Inc. Stock 12‑Month Price Target Raised to $36.31, Implies 38% Upside - TradingView
IMNM Maintains Buy Rating by Truist Securities -- Price Target R - GuruFocus
Immunome (NASDAQ:IMNM) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Immunome, Inc. Stock 12‑Month Price Target Raised to $36.15, Implies 38% Upside - TradingView
IMNM Maintains Outperform by Wedbush -- Price Target Raised to $35 - GuruFocus
Immunome stock hits 52-week high at 27.68 USD - Investing.com
Immunome Inc. SEC Filing (Aug 12, 2026) - Stock Titan
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome (NASDAQ:IMNM) Shares Gap Down on Disappointing Earnings - MarketBeat
IMNM SWOT Analysis: Positive Pipeline Developments Amidst Financ - GuruFocus
Immunome Q2 Results: EPS Misses Estimate, Losses Widen 30% YoY - scanx.trade
Oncology firm Immunome's Q2 net loss widens as R&D costs rise - TradingView
Immunome (IMNM) widens losses as it funds oncology pipeline with $520M cash - Stock Titan
Immunome (NASDAQ:IMNM) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS - MarketBeat
Immunome Inc. Q2 2026: Revenue $0 Net loss $73.1M, EPS $(0.65) — 10-Q Summary - TradingView
Immunome reports Q2 2026 net loss $73.1M, cash and marketable securities $520.0M - TradingView
Immunome, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
IMNM: FDA accepted NDA for varegacestat; Q2 net loss $73.1M, cash $520M, pipeline advancing - TradingView
Immunome: Expect Current Cash Position to Fund Ops Into 2028 >IMNM - Moomoo
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
California State Teachers Retirement System Has $2.44 Million Stock Position in Immunome, Inc. $IMNM - MarketBeat
Trading the Move, Not the Narrative: (IMNM) Edition - Stock Traders Daily
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 20,840 Shares - MarketBeat
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 15,248 Shares - MarketBeat
Immunome, Inc. expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Enterprise value to EBITDA forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Price to sales forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Immunome, Inc. (IMNM) Stock Analysis: Unpacking the 38.53% Potential Upside in Biotechnology - directorstalkinterviews.com
Immunome, Inc. (IMNM) stock price, news, quote and history - Yahoo Finance Australia
Immunome CBO Kinney Horn sells $2.27m in company stock - Investing.com
Immunome CBO Kinney Horn sells $2.27m in company stock By Investing.com - Investing.com UK
Immunome (NASDAQ:IMNM) Insider Sells $2,273,555.44 in Stock - MarketBeat
IMNM (IMNM) investor ABHMC II LLC plans sale of 108,504 common shares - Stock Titan
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Insider at IMNM (NASDAQ: IMNM) plans sale of 90,616 shares - Stock Titan
Edgestream Partners L.P. Makes New $1.31 Million Investment in Immunome, Inc. $IMNM - MarketBeat
Immunome Stock Price Forecast. Should You Buy IMNM? - StockInvest.us
Immunome, Inc. (IMNM) Stock Report: Analyst Consensus Suggests a 54.98% Upside Potential - directorstalkinterviews.com
(IMNM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunome Inc. (IMNM) Q1 2026 Earnings: EPS Beat Estimate as Company Advances PipelineEarnings Surprise Stocks - dars.gov.et
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):